Skip to main content
Log in

Dapagliflozin as add-on to metformin may reduce T2DM burden in China

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • Hu S, et al. Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus. Applied Health Economics and Health Policy : 12 Aug 2020. Available from: URL: https://doi.org/10.1007/s40258-020-00603-7

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dapagliflozin as add-on to metformin may reduce T2DM burden in China. PharmacoEcon Outcomes News 860, 15 (2020). https://doi.org/10.1007/s40274-020-7061-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7061-5

Navigation